Educating Califf: Eyes opened on PDUFA, patient advocates
This article was originally published in Scrip
Dr Robert Califf, the FDA's deputy commissioner of medical products and tobacco – and someone who has been widely speculated to be the next permanent chief – said his perspectives about a lot of things have changed since joining the agency this past winter after spending decades in academia.
You may also be interested in...
Regulators pledge to explore the use of real-world evidence, strengthen the patient's voice in drug review, and boost the agency's postmarketing surveillance abilities as part of sixth round of user fee program with industry.
Under round six of the user fee agreement with industry, the FDA is pledging to explore the use of real-world evidence, strengthen the patient's voice in the drug review process and boost the agency's postmarketing surveillance abilities.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.